Beneficial irAE, along with other clinical characteristics (gender, age, ECOG PS score, tumor stage, liver metastasis, peritoneal metastasis, HER2 expression status, line of anti-PD-1 treatment, year of anti-PD-1 treatment, CCI, NLR, CONUT score), were considered as candidate variables for the predictive model. This evidence concerns the gene ERBB2 and neoplasm.